Idelalisib
Dec. 25, 2024
What is Idelalisib? - GoodRx Idelalisib—targeting PI3Kδ in patients with B-cell malignancies | Nature Reviews Clinical Oncology Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ - ScienceDirect Idelalisib